Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Contact Us
HCPs
English
français
Canada
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts
History
Corporate Philosophy
About Takeda Canada
Message from the GM
Contact Us
Our Partnerships
Compliance
Takeda Worldwide
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Conditions We Treat
ADHD
Crohn's Disease
Gastro esophageal reflux disease (GERD, heartburn)
Gaucher Disease
Hereditary Angioedema
Hunter Syndrome
Lung Cancer
Multiple Myeloma
Short Bowel Syndrome
Ulcerative Colitis
Our Medicines
Medications Return Program
Helping Canadian Patients
Our Pipeline of New Treatments
OnePath Patient Support Program
Vyvanse Assistance Program
How Takeda Canada does Business
Canadian R&D Initiatives
Our Stories
Our Stories
Find out Takeda's stories related on Innovation, Caring and Heritage
Learn more
Innovation
Caring
Rare Diseases Patient Story
Multiple Myeloma Patient Story
IBD Patient Story
Heritage
Takeda Canada's History
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Our Commitment
Giving Back to the Community
Product Donations
Grants, Donations and Sponsorships
COVID-19
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
News Releases
News Releases
Enter
Year of release
2020
2019
2018
2017
2016
2015
2014
September, 2022
September 20, 2022
2022-09-20
Health Canada approves Takeda’s LIVTENCITY™ (maribavir)
September 7, 2022
2022-09-07
Takeda Canada Partners with the CIHR to Advance Research in Rare Diseases
July, 2022
July 25, 2022
2022-07-25
Takeda Canada Innovation Challenge Zoomer Radio Interview
July 6, 2022
2022-07-06
Health Canada approves HyQvia a new treatment for Canadians with immune deficiencies
June, 2022
June 7, 2022
2022-06-07
Takeda Canada applauds Quebecs new Rare Disease Policy
May, 2022
May 11, 2022
2022-05-11
Takeda Canada Innovation Challenge Awarded to Pentavere to Accelerate Rare Disease Diagnosis and Care Using New AI Technology
April, 2022
April 28, 2022
2022-04-28
Hema-Quebec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO
February, 2022
February 28, 2022
2022-02-28
Canadians are encouraged to Rethink Rare on Rare Disease Day
1
2
3
4
5
TOP
Close
